In a recent #SurvivorNet feature, Dr. Akash Patnaik, MD, PhD, highlights growing momentum in precision-based targeted therapies, immune-based approaches, and radioligand treatments such as FPI-2265 for advanced prostate cancer.
@uchicagomedicine.bsky.social
https://ow.ly/vnZO50ZR6Yq